Literature DB >> 32525551

A Positive Feedback Loop Between c-Myc Upregulation, Glycolytic Shift, and Histone Acetylation Enhances Cancer Stem Cell-like Property and Tumorigenicity of Cr(VI)-transformed Cells.

Marco Clementino1, Jie Xie1, Ping Yang1, Yunfei Li1, Hsuan-Pei Lin1, William K Fenske1, Hua Tao1, Kazuya Kondo2, Chengfeng Yang1, Zhishan Wang1.   

Abstract

Chronic hexavalent chromium [Cr(VI)] exposure causes lung cancer and other types of cancer; however, the mechanism of Cr(VI) carcinogenesis remains to be clearly defined. Our recent study showed that chronic Cr(VI) exposure upregulates the proto oncogene c-Myc expression, which contributes significantly to Cr(VI)-induced cell transformation, cancer stem cell (CSC)-like property and tumorigenesis. c-Myc is a master regulator of cancer cell abnormal metabolism and accumulating evidence suggests that metabolism dysregulation plays an important role in both cancer development and progression. However, little is known about the role of metabolism dysregulation in Cr(VI) carcinogenesis. This study was performed to investigate the potential role and mechanism of metabolism dysregulation in Cr(VI) carcinogenesis. It was found that Cr(VI)-transformed cells display glycolytic shift, which depends on the upregulation of c-Myc. The glycolytic shift in Cr(VI)-transformed cells led to increased production of acetyl coenzyme A (acetyl-CoA) and elevation of histone acetylation. This, in turn, upregulated the expression of an acetyl-CoA producing key enzyme ATP citrate lyase and c-Myc, forming a positive feedback loop between the upregulation of c-Myc expression, glycolytic shift and increased histone acetylation. It was further determined that glucose depletion not only reverses the glycolytic shift in Cr(VI)-transformed cells, but also significantly reduces their growth, CSC-like property and tumorigenicity. These findings indicate that glycolytic shift plays an important role in maintaining malignant phenotypes of Cr(VI)-transformed cells, suggesting that metabolism dysregulation is critically involved in Cr(VI) carcinogenesis.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ATP citrate lyase; acetyl-CoA; c-Myc; cancer stem cell-like property; carcinogenesis; glycolytic shift; hexavalent chromium

Year:  2020        PMID: 32525551      PMCID: PMC7553706          DOI: 10.1093/toxsci/kfaa086

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  31 in total

Review 1.  Regulation of chromatin by histone modifications.

Authors:  Andrew J Bannister; Tony Kouzarides
Journal:  Cell Res       Date:  2011-02-15       Impact factor: 25.617

2.  Perfluorooctanoic acid effects on steroid hormone and growth factor levels mediate stimulation of peripubertal mammary gland development in C57BL/6 mice.

Authors:  Yong Zhao; Ying S Tan; Sandra Z Haslam; Chengfeng Yang
Journal:  Toxicol Sci       Date:  2010-01-29       Impact factor: 4.849

3.  MYC, metabolism, cell growth, and tumorigenesis.

Authors:  Chi V Dang
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

Review 4.  Epigenetic and metabolic regulation of breast cancer stem cells.

Authors:  Hui-xin Liu; Xiao-li Li; Chen-fang Dong
Journal:  J Zhejiang Univ Sci B       Date:  2015-01       Impact factor: 3.066

5.  Upregulation of histone-lysine methyltransferases plays a causal role in hexavalent chromium-induced cancer stem cell-like property and cell transformation.

Authors:  Zhishan Wang; Jianjun Wu; Brock Humphries; Kazuya Kondo; Yiguo Jiang; Xianglin Shi; Chengfeng Yang
Journal:  Toxicol Appl Pharmacol       Date:  2018-01-31       Impact factor: 4.219

Review 6.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

Review 7.  The Emerging Hallmarks of Cancer Metabolism.

Authors:  Natalya N Pavlova; Craig B Thompson
Journal:  Cell Metab       Date:  2016-01-12       Impact factor: 27.287

Review 8.  Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.

Authors:  Elanor N Wainwright; Paola Scaffidi
Journal:  Trends Cancer       Date:  2017-05-05

Review 9.  Role of novel histone modifications in cancer.

Authors:  Muthu K Shanmugam; Frank Arfuso; Surendar Arumugam; Arunachalam Chinnathambi; Bian Jinsong; Sudha Warrier; Ling Zhi Wang; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi; Manikandan Lakshmanan
Journal:  Oncotarget       Date:  2017-12-17

Review 10.  Reciprocal Regulation of Metabolic Reprogramming and Epigenetic Modifications in Cancer.

Authors:  Xilan Yu; Rui Ma; Yinsheng Wu; Yansheng Zhai; Shanshan Li
Journal:  Front Genet       Date:  2018-09-19       Impact factor: 4.599

View more
  4 in total

1.  Inhibition of PKCε induces primordial germ cell reprogramming into pluripotency by HIF1&2 upregulation and histone acetylation.

Authors:  Adrian Moratilla; Diego Sainz de la Maza; Marta Cadenas Martin; Pilar López-Iglesias; Pilar González-Peramato; Maria P De Miguel
Journal:  Am J Stem Cells       Date:  2021-02-15

Review 2.  Mechanisms of the synergistic lung tumorigenic effect of arsenic and benzo(a)pyrene combined- exposure.

Authors:  Zhishan Wang
Journal:  Semin Cancer Biol       Date:  2021-05-07       Impact factor: 15.707

Review 3.  Abnormal lipid synthesis as a therapeutic target for cancer stem cells.

Authors:  Si-Yu Wang; Qin-Chao Hu; Tong Wu; Juan Xia; Xiao-An Tao; Bin Cheng
Journal:  World J Stem Cells       Date:  2022-02-26       Impact factor: 5.326

4.  LncRNA DUXAP10 Upregulation and the Hedgehog Pathway Activation Are Critically Involved in Chronic Cadmium Exposure-Induced Cancer Stem Cell-Like Property.

Authors:  Hsuan-Pei Lin; Zhishan Wang; Chengfeng Yang
Journal:  Toxicol Sci       Date:  2021-10-27       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.